196 related articles for article (PubMed ID: 25990504)
1. VEGF111b, a C-terminal splice variant of VEGF-A and induced by mitomycin C, inhibits ovarian cancer growth.
Li X; Gu F; Niu C; Wang Y; Liu Z; Li N; Pan B; He D; Kong J; Zhang S; Wang X; Yao Y; Zheng L
J Transl Med; 2015 May; 13():164. PubMed ID: 25990504
[TBL] [Abstract][Full Text] [Related]
2. VEGF111b, a new member of VEGFxxxb isoforms and induced by mitomycin C, inhibits angiogenesis.
Gu F; Li X; Kong J; Pan B; Sun M; Zheng L; Yao Y
Biochem Biophys Res Commun; 2013 Nov; 441(1):18-24. PubMed ID: 24125722
[TBL] [Abstract][Full Text] [Related]
3. VEGF
Boudria A; Abou Faycal C; Jia T; Gout S; Keramidas M; Didier C; Lemaître N; Manet S; Coll JL; Toffart AC; Moro-Sibilot D; Albiges-Rizo C; Josserand V; Faurobert E; Brambilla C; Brambilla E; Gazzeri S; Eymin B
Oncogene; 2019 Feb; 38(7):1050-1066. PubMed ID: 30194450
[TBL] [Abstract][Full Text] [Related]
4. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.
Rennel E; Waine E; Guan H; Schüler Y; Leenders W; Woolard J; Sugiono M; Gillatt D; Kleinerman E; Bates D; Harper S
Br J Cancer; 2008 Apr; 98(7):1250-7. PubMed ID: 18349828
[TBL] [Abstract][Full Text] [Related]
5. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.
Nowak DG; Woolard J; Amin EM; Konopatskaya O; Saleem MA; Churchill AJ; Ladomery MR; Harper SJ; Bates DO
J Cell Sci; 2008 Oct; 121(Pt 20):3487-95. PubMed ID: 18843117
[TBL] [Abstract][Full Text] [Related]
6. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.
Gao F; Vasquez SX; Su F; Roberts S; Shah N; Grijalva V; Imaizumi S; Chattopadhyay A; Ganapathy E; Meriwether D; Johnston B; Anantharamaiah GM; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R
Integr Biol (Camb); 2011 Apr; 3(4):479-89. PubMed ID: 21283904
[TBL] [Abstract][Full Text] [Related]
7. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
[TBL] [Abstract][Full Text] [Related]
8. Comparative insight into expression of recombinant human VEGF111b, a newly identified anti-angiogenic isoform, in eukaryotic cell lines.
Dehghanian F; Hojati Z
Gene; 2014 Dec; 553(1):57-62. PubMed ID: 25284510
[TBL] [Abstract][Full Text] [Related]
9. Integrin alpha x stimulates cancer angiogenesis through PI3K/Akt signaling-mediated VEGFR2/VEGF-A overexpression in blood vessel endothelial cells.
Wang J; Yang L; Liang F; Chen Y; Yang G
J Cell Biochem; 2019 Feb; 120(2):1807-1818. PubMed ID: 30873824
[TBL] [Abstract][Full Text] [Related]
10. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer.
Wu W; Yu LH; Ma B; Xu MJ
PLoS One; 2014; 9(3):e89841. PubMed ID: 24598933
[TBL] [Abstract][Full Text] [Related]
11. VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.
Shathasivam P; Kollara A; Spybey T; Park S; Clarke B; Ringuette MJ; Brown TJ
Br J Cancer; 2017 Apr; 116(8):1065-1076. PubMed ID: 28301874
[TBL] [Abstract][Full Text] [Related]
12. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
14. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression.
Park MS; Kim BR; Dong SM; Lee SH; Kim DY; Rho SB
Oncotarget; 2014 Jul; 5(13):4935-44. PubMed ID: 24952732
[TBL] [Abstract][Full Text] [Related]
15. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Ca
Liu Z; Zhang S; Hou F; Zhang C; Gao J; Wang K
Int J Cancer; 2019 May; 144(9):2215-2226. PubMed ID: 30243029
[TBL] [Abstract][Full Text] [Related]
17. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
[TBL] [Abstract][Full Text] [Related]
18. sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways.
Kim BR; Seo SH; Park MS; Lee SH; Kwon Y; Rho SB
Oncotarget; 2015 Oct; 6(31):31830-43. PubMed ID: 26378810
[TBL] [Abstract][Full Text] [Related]
19. New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation.
Delcombel R; Janssen L; Vassy R; Gammons M; Haddad O; Richard B; Letourneur D; Bates D; Hendricks C; Waltenberger J; Starzec A; Sounni NE; Noël A; Deroanne C; Lambert C; Colige A
Angiogenesis; 2013 Apr; 16(2):353-71. PubMed ID: 23254820
[TBL] [Abstract][Full Text] [Related]
20. FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway.
Zhu H; Diao S; Lim V; Hu L; Hu J
Acta Biochim Biophys Sin (Shanghai); 2019 May; 51(5):509-516. PubMed ID: 30939187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]